Werkgroep Cardiologische centra Nederland

PARAGON (Completed)

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety. LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction
Medicine
LCZ696
Population
Heart failure
Phase
III
Starting year
2013
More information
ClinicalTrials.gov

Director of Study

dr. G.C.M. Linssen (Cardioloog)
Almelo, ZGT

PARAGON: News